Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Thursday, February 21, 2019
AbbVie and Eisai Announce Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA is the First in Japan to be Approved for the Treatment of Hidradenitis Suppurativa
Wednesday, February 13, 2019
Eisai Submits Application in Europe Seeking Approval for Fycompa as Treatment for Pediatric Patients With Epilepsy
Monday, February 4, 2019
Eisai and Purdue Pharma Present Efficacy and Safety Data from Second Pivotal Phase 3 Study
Wednesday, January 30, 2019
Eisai's Supplementary New Drug Application Submitted In Japan for Fycompa
Tuesday, January 22, 2019
Eisai Listed as a Global 100 Most Sustainable Corporation for the Fourth Time
Friday, January 18, 2019
Eisai's Notification Regarding Results of Voluntary Retirement Program
Tuesday, January 15, 2019
Eisai to Present Results of Post-Hoc Analyses of Lenvima (Lenvatinib) Phase III Reflect Study in Hepatocellular Carcinoma at 2019 Gastrointestinal Cancers Symposium
Eisai's New Drug Application for Insomnia Disorder Treatment Lemborexant Submitted in the United States
Friday, January 4, 2019
Eisai's Etak Antimicrobial Spray Alpha Wins Nikkei Business Daily Awards for Superiority at the 2018 Nikkei Superior Products and Services Awards
Eisai's New Drug Application for Perampanel Designated for Priority Review by China National Medical Products Administration

Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: